Trial
NCT04396366
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
Innovative Medicines Initiative
Condition
Bronchiectasis
Intervention
QBW251
Why stopped
Strategic business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-26